XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona to Present at the Stifel 2020 Virtual Jaws and Paws Conference on May 27th

Dentsply Sirona to Present at the Stifel 2020 Virtual Jaws and Paws Conference on May 27th

CHARLOTTE, N.C., May 25, 2020 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that it will participate in the Stifel 2020 Jaws and Paws Conference on May 27th.

Don Casey, Chief Executive Officer, will represent the company and is scheduled to participate in a fireside chat at 4:45PM Eastern Time.  Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting   A replay of the presentation will also be available on the Dentsply Sirona website at

About Dentsply Sirona

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 132-year history of innovation and service to the dental industry and patients worldwide.  Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands.  As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry.  The Company’s shares of common stock are listed in the United States on Nasdaq under the symbol XRAY.  Visit for more information about Dentsply Sirona and its products.

Contact Information:

Investors:

John Sweeney, CFA, IRC

Vice President, Investor Relations



 

EN
25/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dentsply Sirona Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 March 2026 in which we reassessed the appropriateness of the ratings in the context ...

Dentsply Sirona Inc: 2 directors

Two Directors at Dentsply Sirona Inc bought/maiden bought 55,000 shares at between 13.469USD and 14.148USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...

 PRESS RELEASE

Dentsply Sirona to Participate in the Leerink Partners Global Healthca...

Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026 CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 10, 2026, at 10:00 a.m. EST. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About Dentspl...

 PRESS RELEASE

Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Pro...

Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook News Summary Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of taxQ4 2025 adjusted EPS of $0.27FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50(1)Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch